Home › Research › Cognitive tests and assessment
The Validity and Reliability of the Turkish Version of the Rowland Universal Dementia Assessment Scale (RUDAS) for Alzheimer’s Disease and Mild Cognitive Impairment
Görkem Tutal Gürsoy, Yıldız Kaya. Journal of Drug Delivery and Therapeutics, 2025-01-15
Topic: Risk, prevention and care in population studies
Plain-language summary
The Cronbach alpha coefficient of the RUDAS scale is 0.8529. In our analysis, the scale was found to be highly reliable. In our study, the difference between the RUDAS scale mean scores of the groups was found to be statistically significant (p<0.001). In estimating the Alzheimer's Disease patient group, the AUC value under the curve of the RUDAS score was obtained as 0.998, and the mild cognitive impairment AUC value was obtained as 0.971, which was found to be significant. (p<0.001). The degree of the relationship between the RUDAS scale and the MMSE scale was found to be very strong and statistically significant in the positive direction. (r=0.938 p<0.001) This study showed that the Turkish version of the RUDAS is a valid and reliable scale for the evaluation and follow-up of Alzheimer's disease and mild cognitive impairment in the Turkish population.
What this study adds
Evidence grade: Low
The record lists 87 participants. This study found the Turkish version of the RUDAS scale to be valid and reliable for evaluating Alzheimer's disease and mild cognitive impairment. It is a test-validation study and does not address treatment, cure or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gürsoy, G. T., & Kaya, Y. (2025). The Validity and Reliability of the Turkish Version of the Rowland Universal Dementia Assessment Scale (RUDAS) for Alzheimer’s Disease and Mild Cognitive Impairment. Journal of Drug Delivery and Therapeutics. https://doi.org/10.22270/jddt.v15i1.6940
Vancouver
Gürsoy GT, Kaya Y. The Validity and Reliability of the Turkish Version of the Rowland Universal Dementia Assessment Scale (RUDAS) for Alzheimer’s Disease and Mild Cognitive Impairment. Journal of Drug Delivery and Therapeutics. 2025. doi:10.22270/jddt.v15i1.6940.
BibTeX
@article{gursoy2025-682bd5c6,
author = {Gürsoy, Görkem Tutal and Kaya, Yıldız},
title = {{The Validity and Reliability of the Turkish Version of the Rowland Universal Dementia Assessment Scale (RUDAS) for Alzheimer’s Disease and Mild Cognitive Impairment}},
journal = {Journal of Drug Delivery and Therapeutics},
year = {2025},
doi = {10.22270/jddt.v15i1.6940},
url = {https://doi.org/10.22270/jddt.v15i1.6940}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The Cronbach alpha coefficient of the RUDAS scale is 0.8529.
- In our analysis, the scale was found to be highly reliable.
- In our study, the difference between the RUDAS scale mean scores of the groups was found to be statistically significant (p<0.001).
- In estimating the Alzheimer's Disease patient group, the AUC value under the curve of the RUDAS score was obtained as 0.998, and the mild cognitive impairment AUC value was obtained as 0.971, which was found to be significant.
- The degree of the relationship between the RUDAS scale and the MMSE scale was found to be very strong and statistically significant in the positive direction.
Why it matters
This study found the Turkish version of the RUDAS scale to be valid and reliable for evaluating Alzheimer's disease and mild cognitive impairment. It is a test-validation study and does not address treatment, cure or prevention.
Study details
- Participants87
- Evidence strengthLow
How this study scored 33/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 32 of the 97 points we could judge it on, which is 33 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Drug Delivery and Therapeutics) |
| Journal's citation record | 0 / 4 | Journal of Drug Delivery and Therapeutics: journal h-index 48 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 87 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 1 / 6 | Cited 0.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Yıldız Kaya: h-index 8 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 32 / 97 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 32 of the 97 points we could judge it on is 33 out of 100. |
| Total | 33 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.22270/jddt.v15i1.6940
- Original source →
- Free full text: Journal of Drug Delivery and Therapeutics →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Cognitive tests and assessment from nearby years
Also tagged “prevalence”
1,223 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,223 tagged studies.